Public Health, Epidemiology and Biostatistics, University of Birmingham, UK.
Br J Gen Pract. 2013 Jan;63(606):e55-62. doi: 10.3399/bjgp13X660788.
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. However, much of the disease burden remains undiagnosed.
To compare the yield and cost effectiveness of two COPD case-finding approaches in primary care.
Pilot randomised controlled trial in two general practices in the West Midlands, UK.
A total of 1634 ever-smokers aged 35-79 years with no history of COPD or asthma were randomised into either a 'targeted' or 'opportunistic' case-finding arm. Respiratory questionnaires were posted to patients in the 'targeted' arm and provided to patients in the 'opportunistic' arm at routine GP appointments. Those reporting at least one chronic respiratory symptom were invited for spirometry. COPD was defined as pre-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC)<0.7 and FEV1<80% of predicted. Primary outcomes were the difference in the proportion of patients diagnosed with COPD and the cost per case detected.
Twenty-six per cent (212/815) in the 'targeted' and 13.6% (111/819) in the 'opportunistic' arm responded to the questionnaire and 78.3% (166/212) and 73.0% (81/111), respectively, reported symptoms; 1.2% (10/815) and 0.7% (6/819) of patients in the 'targeted' and 'opportunistic' arms were diagnosed with COPD (difference in proportions = 0.5% [95% confidence interval {CI} = -0.5% to 3.08%]). Over a 12-month period, the 'opportunistic' case-finding yield could be improved to 1.95% (95% CI = 1.0% to 2.9%). The cost-per case detected was £424.56 in the 'targeted' and £242.20 in the 'opportunistic' arm.
Opportunistic case finding may be more effective and cost effective than targeting patients with a postal questionnaire alone. A larger randomised controlled trial with adequate sample size is required to test this.
慢性阻塞性肺疾病(COPD)是发病率和死亡率的主要原因。然而,大部分疾病负担仍未得到诊断。
比较两种 COPD 病例发现方法在初级保健中的效果和成本效益。
英国西米德兰兹郡两个普通诊所的试点随机对照试验。
共纳入 1634 名年龄在 35-79 岁、有吸烟史但无 COPD 或哮喘病史的患者,随机分为“目标”或“机会”病例发现组。将呼吸问卷寄给“目标”组的患者,并在常规 GP 预约时提供给“机会”组的患者。报告至少一种慢性呼吸道症状的患者被邀请进行肺活量测定。COPD 的定义为支气管扩张剂前一秒用力呼气量/用力肺活量(FEV1/FVC)<0.7 和 FEV1<80%预计值。主要结局是诊断为 COPD 的患者比例差异和每例检测的成本。
“目标”组中 26%(212/815)和“机会”组中 13.6%(111/819)的患者对问卷做出了回应,分别有 78.3%(166/212)和 73.0%(81/111)的患者报告了症状;“目标”组和“机会”组分别有 1.2%(10/815)和 0.7%(6/819)的患者被诊断为 COPD(比例差异=0.5%[95%置信区间{CI}=-0.5%至 3.08%])。在 12 个月的时间里,“机会”病例发现的效果可以提高到 1.95%(95%CI=1.0%至 2.9%)。每例检测的成本分别为“目标”组 424.56 英镑和“机会”组 242.20 英镑。
与仅使用邮寄问卷靶向患者相比,机会性病例发现可能更有效且具有成本效益。需要进行更大规模的随机对照试验来验证这一点。